NCT05312892View on ClinicalTrials.gov

Sympathetic Mechanisms in Obesity-Crossover Design

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 20, 2022

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2029

Conditions
ObesityHypertension
Interventions
DRUG

Amlodipine

Subjects will receive either an antihypertensive (amlodipine or moxonidine) medication or placebo for two weeks, then cross over to the second arm, and then after 2 weeks of the second drug/placebo, will be switched to the third arm.

DRUG

Moxonidine

Moxonidine

DRUG

Placebo

Placebo

Trial Locations (1)

37232

RECRUITING

Vanderbilt University Medical Center, Nashville

All Listed Sponsors
lead

Vanderbilt University Medical Center

OTHER